Suppressor transfer RNAs, a class of molecules that can override premature stop signals in DNA’s protein-coding instructions, have been used to restore full-length p53 from nonsense-mutant TP53 genes, and in mouse models the approach drove substantial tumour regression, according to a study published in Nature Communications.
Nonsense mutations introduce premature stop codons into tumour suppressor genes, truncating the proteins they encode and contributing to cancer initiation and progression. These mutations have long been considered undruggable, because a single conventional agent struggles to rescue the functional impairment caused by many different truncated protein variants.
The researchers observed that suppressor tRNAs could overcome diverse nonsense mutations in TP53, restoring expression of full-length p53 and its function. The engineered tRNAs enabled high-fidelity incorporation of optimal amino acids at the mutation site, and in some cases the resulting p53 variants showed enhanced transcriptional activity compared with restored wild-type p53, suppressing tumour cell proliferation.
Notably, the sup-tRNA-produced p53 variants reduced cancer cell colony area by up to 82 percent in cell culture experiments, exceeding the activity of simply restored wild-type p53.
To extend the strategy beyond TP53, the team developed a computational model that guides sup-tRNA design using in silico saturation mutagenesis, allowing targeted readthrough of different nonsense-mutant tumour suppressor genes.
In two xenograft models carrying nonsense-mutant TP53, lipid nanoparticle delivery of sup-tRNAs produced up to a 74 percent reduction in tumour volume, an effect the authors attribute to robust recovery of p53 expression and function.
As a monotherapy, the sup-tRNA treatment surpassed nab-paclitaxel chemotherapy in efficacy in the tested models. When combined with chemotherapy, the treatment induced near-complete tumour regression, with a maximum of 93 percent reduction in tumour volume, and no detectable toxicity was observed in multiple mouse tumour models.
The findings highlight tRNA-based therapy as a promising strategy for rescuing nonsense-mutant TP53. The work was published as an open-access article on 23 October 2026, and the version shared at publication is an accepted manuscript subject to further edits before the final version of record. As with all preclinical xenograft studies, results in mouse models do not establish safety or efficacy in humans, and clinical translation would require further testing.
Subject of Research: Using engineered suppressor tRNAs to restore tumour suppressor protein function from nonsense-mutant TP53 in cancer models
Article Title: Suppressor tRNAs restore functionally enhanced tumour suppressor protein to induce tumour regression
Article References: Kong, B., Zheng, Z., Mi, Z., Dou, Z., Yang, Y., Shen, Y., Dong, L., Lv, J., Li, Y., Liang, Q., Tian, S., & Xia, Q. (2026). Suppressor tRNAs restore functionally enhanced tumour suppressor protein to induce tumour regression. Nature Communications. https://doi.org/10.1038/s41467-026-78578-7
Image Credits: AI Generated
DOI: 10.1038/s41467-026-78578-7
Keywords: suppressor tRNA, TP53, p53, nonsense mutation, tumour suppressor, lipid nanoparticle, xenograft, tumour regression, gene therapy, cancer, readthrough, Nature Communications
News Source: Nathaniel Bowman. (October 29, 2026). Suppressor tRNAs restore mutant p53 and shrink tumours in mice. Scienmag.
